REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL
RNS Number : 4924HMorgan Stanley15 November 2018
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt principal trader is connected:
Shire plc
(d) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
14 NOVEMBER 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - Shire plc
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
11,607,687
1.48
29,712,301
3.79
(2) Cash-settled derivatives:
29,306,309
3.74
10,895,271
1.39
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
185,000
0.02
185,000
0.02
TOTAL:
41,098,996
5.24
40,792,572
5.20
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
PURCHASES
1,756,002
4,537.4560 JPY
4,463.0042 JPY
Ordinary
SALES
1,788,023
4,537.4560 JPY
4,463.0042 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
LONG
2500
4500.0000 JPY
Ordinary
CFD
SHORT
1500
4498.7333 JPY
Ordinary
CFD
LONG
900
4500.0000 JPY
Ordinary
CFD
LONG
32800
4490.1432 JPY
Ordinary
CFD
SHORT
300
4487.0000 JPY
Ordinary
CFD
SHORT
600
4500.0000 JPY
Ordinary
CFD
LONG
200
4509.5000 JPY
Ordinary
CFD
SHORT
600
4504.6666 JPY
Ordinary
CFD
LONG
1100
4507.3636 JPY
Ordinary
CFD
LONG
11100
4500.0000 JPY
Ordinary
CFD
SHORT
5200
4518.0000 JPY
Ordinary
CFD
LONG
1500
4517.8000 JPY
Ordinary
CFD
SHORT
700
4501.5714 JPY
Ordinary
CFD
LONG
9500
4506.4258 JPY
Ordinary
CFD
LONG
21200
4500.1981 JPY
Ordinary
CFD
SHORT
4200
4492.0000 JPY
Ordinary
CFD
LONG
700
4496.1428 JPY
Ordinary
CFD
SHORT
800
4492.0000 JPY
Ordinary
CFD
LONG
800
4494.7500 JPY
Ordinary
CFD
SHORT
1800
4497.7777 JPY
Ordinary
CFD
SHORT
30200
4501.2593 JPY
Ordinary
CFD
SHORT
1800
4501.2593 JPY
Ordinary
CFD
SHORT
600
4495.5000 JPY
Ordinary
CFD
SHORT
29700
4503.3569 JPY
Ordinary
CFD
LONG
18300
4504.5628 JPY
Ordinary
CFD
LONG
800
4492.6875 JPY
Ordinary
CFD
SHORT
150000
4500.0563 JPY
Ordinary
CFD
LONG
38800
4500.0286 JPY
Ordinary
CFD
SHORT
56600
4504.9682 JPY
Ordinary
CFD
SHORT
74500
4504.6112 JPY
Ordinary
CFD
LONG
10000
4505.2042 JPY
Ordinary
CFD
SHORT
500
4483.0000 JPY
Ordinary
CFD
LONG
242691
4490.4572 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type e.g. American, European etc.
Expiry date
Option money paid/ received per unit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
N/A
N/A
N/A
N/A
N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
N/A
N/A
N/A
N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
15 NOVEMBER 2018
Contact name:
Craig Horsley
Telephone number:
+44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
4. KEY INFORMATION
Identity of person whose open positions are being disclosed:
Morgan Stanley MUFG Securities Co., Ltd.
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical Company Limited
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product Description e.g call option
Written or Purchased
Number of Securities to which option or derivative relates
Exercise Price Per Unit (USD)
Type
Expiry Date
Ordinary
PUT
PURCHASED
125,000
4507.0000 JPY
European
13/12/2019
Ordinary
CALL
PURCHASED
125,000
4507.0000 JPY
European
13/12/2019
Ordinary
PUT
PURCHASED
60,000
4596.0000 JPY
European
14/06/2019
Ordinary
CALL
PURCHASED
60,000
4596.0000 JPY
European
14/06/2019
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.
The currency of all prices and other monetary amounts should be stated.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFEOEAEFSFSDPFFF
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement